Celldex Therapeutics, Inc.
CLDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,627 | $1,921 | $2,090 | $1,656 |
| - Cash | $28 | $35 | $29 | $39 |
| + Debt | $4 | $3 | $4 | $3 |
| Enterprise Value | $1,603 | $1,889 | $2,064 | $1,620 |
| Revenue | $7 | $7 | $2 | $5 |
| % Growth | 2% | 192% | -49.3% | – |
| Gross Profit | -$157 | -$111 | -$80 | -$49 |
| % Margin | -2,229.8% | -1,614.5% | -3,389.9% | -1,046.2% |
| EBITDA | -$192 | -$139 | -$104 | -$66 |
| % Margin | -2,733.6% | -2,020% | -4,420.9% | -1,420.8% |
| Net Income | -$158 | -$141 | -$112 | -$71 |
| % Margin | -2,248.8% | -2,054.8% | -4,765.6% | -1,516% |
| EPS Diluted | -2.45 | -2.92 | -2.4 | -1.64 |
| % Growth | 16.1% | -21.7% | -46.3% | – |
| Operating Cash Flow | -$158 | -$107 | -$104 | -$61 |
| Capital Expenditures | -$2 | -$2 | -$2 | -$1 |
| Free Cash Flow | -$160 | -$109 | -$106 | -$62 |